asymptomatic
37% risk reduction for progression to symptomatic heart failure can be       achieved with ACE-inhibition in asymptomatic patients with systolic left       ventricular dysfunction (55).
37% risk reduction for progression to symptomatic heart failure can be       achieved with ACE-inhibition in  @SUBJECT$  @PREDICAT$  @OBJECT$  with systolic left       ventricular dysfunction (55).